Related Experiment Video
Updated: Nov 23, 2025
Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Diosgenin Derivatives as Potential Antitumor Agents: Synthesis, Cytotoxicity, and Mechanism of Action
Hong Yin1, Min-Jie Zhang1, Ren-Feng An1
1Department of Natural Medicinal Chemistry, School of Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China.
Abstract:
Thirty-two new diosgenin derivatives were designed, synthesized, and evaluated for their cytotoxic activities in three human cancer cell lines (A549, MCF-7, and HepG2) and normal human liver cells (L02) using an MTT assay in vitro. Most compounds, especially 8, 18, 26, and 30, were more potent when compared with diosgenin. The structure-activity relationship results suggested that the presence of a succinic acid or glutaric acid linker, a piperazinyl amide terminus, and lipophilic cations are all beneficial for promoting cytotoxic activity. Notably, compound 8 displayed excellent cytotoxic activity against HepG2 cells (IC50 = 1.9 μM) and showed relatively low toxicity against L02 cells (IC50 = 18.6 μM), showing some selectivity between normal and tumor cells. Studies on its cellular mechanism of action showed that compound 8 induces G0/G1 cell cycle arrest and apoptosis in HepG2 cells. Predictive studies indicated that p38α mitogen-activated protein kinase (MAPK) is the optimum target of 8 based on its 3D molecular similarity, and docking studies showed that compound 8 fits well into the active site of p38α-MAPK and forms relatively strong interactions with the surrounding amino acid residues. Accordingly, compound 8 may be used as a promising lead compound for the development of new antitumor agents.
Insights
New diosgenin derivatives show potent anticancer activity, particularly compound 8 against HepG2 cells. This compound induces cell cycle arrest and apoptosis, targeting p38α-MAPK, suggesting its potential as a novel antitumor agent.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Cancer Biology
Background:
- Diosgenin, a natural steroidal sapogenin, serves as a precursor for synthesizing various bioactive compounds.
- Developing novel anticancer agents with improved efficacy and selectivity remains a critical challenge in oncology.
Purpose of the Study:
- To design, synthesize, and evaluate novel diosgenin derivatives for their in vitro cytotoxic activities against human cancer cell lines.
- To identify structure-activity relationships (SAR) that enhance cytotoxic potency and selectivity.
- To investigate the cellular mechanism of action and molecular targets of the most promising derivative.
Main Methods:
- Synthesis of 32 new diosgenin derivatives.
- In vitro cytotoxic evaluation using MTT assay against A549, MCF-7, HepG2 cancer cells, and L02 normal liver cells.
- Structure-activity relationship analysis.
- Cellular mechanism studies including cell cycle analysis and apoptosis assays.
- In silico molecular docking and similarity studies to predict molecular targets.
Main Results:
- Most synthesized compounds exhibited enhanced cytotoxic activity compared to diosgenin, with compounds 8, 18, 26, and 30 showing significant potency.
- SAR studies indicated that specific linkers (succinic, glutaric acid), termini (piperazinyl amide), and lipophilic cations positively influence cytotoxic activity.
- Compound 8 demonstrated potent cytotoxicity against HepG2 cells (IC50 = 1.9 μM) with notable selectivity over L02 cells (IC50 = 18.6 μM).
- Compound 8 induced G0/G1 cell cycle arrest and apoptosis in HepG2 cells.
- In silico studies identified p38α-MAPK as a likely molecular target for compound 8, with favorable docking interactions.
Conclusions:
- The novel diosgenin derivatives, particularly compound 8, exhibit promising cytotoxic activity against cancer cells.
- Compound 8's ability to induce cell cycle arrest and apoptosis, coupled with its predicted interaction with p38α-MAPK, highlights its potential as a lead compound.
- Further development of compound 8 could lead to new therapeutic strategies for cancer treatment.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
01:25Mutagenicity and Carcinogenicity
01:10Drugs that Destabilize Microtubules
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...